BICX.jpg
BioCorRx’s Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida
March 28, 2019 08:00 ET | BioCorRx Inc
ANAHEIM, CA, March 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company), a developer and provider of advanced solutions in the treatment of substance abuse...
BICX.jpg
BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement
March 27, 2019 07:37 ET | BioCorRx Inc
ANAHEIM, CA, March 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance abuse...
BICX.jpg
BioCorRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019
March 14, 2019 08:00 ET | BioCorRx Inc
ANAHEIM, CA, March 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use...
BICX.jpg
BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder
February 26, 2019 08:00 ET | BioCorRx Inc
ANAHEIM, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use...
BICX.jpg
BioCorRx Appoints Two Finance Veterans to the Board of Directors
February 25, 2019 08:00 ET | BioCorRx Inc
ANAHEIM, CA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (“Company”), a developer and provider of advanced solutions in the treatment of substance use disorders,...
BICX.jpg
BioCorRx Announces Formation of Scientific Advisory Board
February 19, 2019 10:26 ET | BioCorRx Inc
ANAHEIM, CA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BICX.jpg
BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
January 23, 2019 08:00 ET | BioCorRx Inc
ANAHEIM, CA, Jan. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX; BICXD) (the “Company”), a developer and provider of advanced solutions in the treatment of substance...
BICX.jpg
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder
January 22, 2019 07:30 ET | BioCorRx Inc
ANAHEIM, CA, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...
BICX.jpg
BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families
October 19, 2018 07:30 ET | BioCorRx Inc
 Issued patents, in addition to other intellectual property (IP) rights, cover hydrophobic drug-delivery material for BICX101 Divisional patent applications filed to strengthen BioCorRx’s ...
BICX.jpg
BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001
October 09, 2018 08:00 ET | BioCorRx Inc
ANAHEIM, CA, Oct. 09, 2018 (GLOBE NEWSWIRE) -- VDM-001 represents potential alternative to naloxone for overdose reversal; Potential to reduce cravings from substance use disorder  via...